Abivax reports 2023 financial results and operational update

Abivax reports 2023 financial results and operational update raised eur 500m in 2023, including a eur 130m capital increase, two structured debt financing transactions aggregating eur 150m and eur 223.3m initial public offering on the nasdaq global market sufficient funds to finance operations into q4 2025, including through the announcement of top-line data from the phase 3 abtect induction trials of obefazimod in ulcerative colitis (uc) implementation of u.s. and european operational infrastructure to progress the company's ongoing clinical and preclinical programs paris, france, april 2, 2024, 8:30 a.m. cest – abivax sa (euronext paris & nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced its 2023 annual financial results, as of december 31, 2023, and provided an update on the progress of its development programs.
ABVX Ratings Summary
ABVX Quant Ranking